Skip to main content

Advertisement

SpringerLink
Log in

RETRACTED ARTICLE: Gut microbiota and related diseases: clinical features

  • Selected Paper: Gut Microbiota and Related Diseases
  • Published:
Internal and Emergency Medicine Aims and scope Submit manuscript

This article was retracted on 10 December 2014

Abstract

Intestinal microbiota is essential for gut homeostasis. Specifically, the microorganisms inhabiting the gut lumen interact with the intestinal immune system, supply key nutrients for the major components of the gut wall, and modulate energy metabolism. Host–microbiome interactions can be either beneficial or deleterious, driving gastrointestinal lymphoid tissue activities and shaping gut wall structures. This overview briefly focuses on the potential role played by abnormalities in gut microbiota and relative responses of the gastrointestinal tract in the determination of important pathological conditions such as the irritable bowel syndrome, inflammatory bowel diseases and colorectal cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Barbara G, Stanghellini V, Brandi G, Cremon C, Di Nardo G, De Giorgio R, Corinaldesi R (2005) Interactions between commensal bacteria and gut sensorimotor function in health and disease. Am J Gastroenterol 100(11):2560–2568

    Article  CAS  PubMed  Google Scholar 

  2. Longstreth GF, Thompson WG, Chey WD, Houghton LA, Mearin F, Spiller RC (2006) Functional bowel disorders. Gastroenterology 130(5):1480–1491

    Article  PubMed  Google Scholar 

  3. Malinen E, Rinttilä T, Kajander K, Mättö J, Kassinen A, Krogius L, Saarela M, Korpela R, Palva A (2005) Analysis of the fecal microbiota of irritable bowel syndrome patients and healthy controls with real-time PCR. Am J Gastroenterol 100(2):373–382

    Article  CAS  PubMed  Google Scholar 

  4. Kassinen A, Krogius-Kurikka L, Mäkivuokko H, Rinttilä T, Paulin L, Corander J, Malinen E, Apajalahti J, Palva A (2007) The fecal microbiota of irritable bowel syndrome patients differs significantly from that of healthy subjects. Gastroenterology 133(1):24–33

    Article  CAS  PubMed  Google Scholar 

  5. Lyra A, Rinttilä T, Nikkilä J, Krogius-Kurikka L, Kajander K, Malinen E, Mättö J, Mäkelä L, Palva A (2009) Diarrhoea-predominant irritable bowel syndrome distinguishable by 16S rRNA gene phylotype quantification. World J Gastroenterol 15(47):5936–5945

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  6. Spiller R, Garsed K (2009) Postinfectious irritable bowel syndrome. Gastroenterology 136(6):1979–1988

    Article  PubMed  Google Scholar 

  7. Schoepfer AM, Schaffer T, Seibold-Schmid B, Müller S, Seibold F (2008) Antibodies to flagellin indicate reactivity to bacterial antigens in IBS patients. Neurogastroenterol Motil 20(10):1110–1118

    Article  CAS  PubMed  Google Scholar 

  8. Preidis GA, Versalovic J (2009) Targeting the human microbiome with antibiotics, probiotics, and prebiotics: gastroenterology enters the metagenomics era. Gastroenterology 136(6):2015–2031

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  9. Moayyedi P, Ford AC, Talley NJ, Cremonini F, Foxx-Orenstein AE, Brandt LJ, Quigley EM (2010) The efficacy of probiotics in the treatment of irritable bowel syndrome: a systematic review. Gut 59(3):325–332

    Article  CAS  PubMed  Google Scholar 

  10. Pimentel M, Park S, Mirocha J, Kane SV, Kong Y (2006) The effect of a nonabsorbed oral antibiotic (rifaximin) on the symptoms of the irritable bowel syndrome: a randomized trial. Ann Intern Med 145(8):557–563

    Article  PubMed  Google Scholar 

  11. Balsari A, Ceccarelli A, Dubini F, Fesce E, Poli G (1982) The fecal microbial population in the irritable bowel syndrome. Microbiologica 5(3):185–194

    CAS  PubMed  Google Scholar 

  12. Wyatt GM, Bayliss CE, Lakey AF, Bradley HK, Hunter JO, Jones VA (1988) The faecal flora of two patients with food-related irritable bowel syndrome during challenge with symptom-provoking foods. J Med Microbiol 26(4):295–299

    Article  CAS  PubMed  Google Scholar 

  13. Madden JAJ, Plummer S, Sen S, Dear K, Tarry S, Hunter JO (2001) Comparison of the caecal and faecal microflora of healthy subjects and patients with irritable bowel syndrome (IBS). Gut 48(Suppl 1):A58

    Google Scholar 

  14. Pimentel M, Chow EJ, Lin HC (2000) Eradication of small intestinal bacterial overgrowth reduces symptoms of irritable bowel syndrome. Am J Gastroenterol 95(12):3503–3506

    Article  CAS  PubMed  Google Scholar 

  15. Pimentel M, Chow EJ, Lin HC (2003) Normalization of lactulose breath testing correlates with symptom improvement in irritable bowel syndrome a double-blind, randomized, placebo-controlled study. Am J Gastroenterol 98(2):412–419

    PubMed  Google Scholar 

  16. Pimentel M, Wallace D, Hallegua D, Chow E, Kong Y, Park S, Lin HC (2004) A link between irritable bowel syndrome and fibromyalgia may be related to findings on lactulose breath testing. Ann Rheum Dis 63(4):450–452

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  17. McCallum R, Schultz C, Sostarich S (2005) Evaluating the role of small intestinal bacterial overgrowth (SIBO) in diarrhea predominant IBS (IBS-D) patients utilizing the glucose breath test. Gastroenterology 128:T1118

    Google Scholar 

  18. Nucera G, Gabrielli M, Lupascu A, Lauritano EC, Santoliquido A, Cremonini F, Cammarota G, Tondi P, Pola P, Gasbarrini G, Gasbarrini A (2005) Abnormal breath tests to lactose, fructose and sorbitol in irritable bowel syndrome may be explained by small intestinal bacterial overgrowth. Aliment Pharmacol Ther 21(11):1391–1395

    Article  CAS  PubMed  Google Scholar 

  19. Pimentel M, Lembo A, Chey WD, Ringel Y, Zakko S, Mareya SM, Shaw AL, Yu J, Bortey E, Forbes WP (2010) Rifaximin treatment for 2 weeks provides acute and sustained relief over 12 weeks of IBS symptoms in non-constipated irritable bowel syndrome: results from 2 North American phase 3 trials (Target 1 and Target 2). Gastroenterology 138(5, Suppl 1):S64–S65

    Article  Google Scholar 

  20. Gasbarrini A, Corazza GR, Gasbarrini G, Montalto M, Di Stefano M, Basilisco G, Parodi A, Usai-Satta P, Vernia P, Anania C, Astegiano M, Barbara G, Benini L, Bonazzi P, Capurso G, Certo M, Colecchia A, Cuoco L, Di Sario A, Festi D, Lauritano C, Miceli E, Nardone G, Perri F, Portincasa P, Risicato R, Sorge M, Tursi A, 1st Rome H2-Breath Testing Consensus Conference Working Group (2009) Methodology and indications of H2-breath testing in gastrointestinal diseases: the Rome Consensus Conference. Aliment Pharmacol Ther 29(Suppl 1):1–49

    PubMed  Google Scholar 

  21. Posserud I, Stotzer PO, Björnsson ES, Abrahamsson H, Simrén M (2007) Small intestinal bacterial overgrowth in patients with irritable bowel syndrome. Gut 56(6):802–808

    Article  PubMed Central  PubMed  Google Scholar 

  22. Maukonen J, Satokari R, Mättö J, Söderlund H, Mattila-Sandholm T, Saarela M (2006) Prevalence and temporal stability of selected clostridial groups in irritable bowel syndrome in relation to predominant faecal bacteria. J Med Microbiol 55(Pt 5):625–633

    Article  CAS  PubMed  Google Scholar 

  23. Turner JR (2009) Intestinal mucosal barrier function in health and disease. Nat Rev Immunol 9(11):799–809

    Article  CAS  PubMed  Google Scholar 

  24. Nusrat A, Turner JR, Madara JL (2000) Molecular physiology and pathophysiology of tight junctions. IV. Regulation of tight junctions by extracellular stimuli: nutrients, cytokines, and immune cells. Am J Physiol Gastrointest Liver Physiol 279(5):G851–G857

    CAS  PubMed  Google Scholar 

  25. Sartor RB (2008) Microbial influences in inflammatory bowel diseases. Gastroenterology 134(2):577–594

    Article  CAS  PubMed  Google Scholar 

  26. Takeda K, Akira S (2005) Toll-like receptors in innate immunity. Int Immunol 17(1):1–14

    Article  CAS  PubMed  Google Scholar 

  27. Dlugosz A, Lindberg G (2010) The expression of toll-like receptor 4 in colon mucosa is as up-regulated in irritable bowel syndrome as it is in inflammatory bowel disease. Gastroenterology 138 (5, Suppl 1):S626

    Google Scholar 

  28. McKernan DP, Gaszner G, Quigley EM, Cryan JF, Dinan TG (2010) Enhanced release of specific TLR-agonist mediated pro-inflammatory cytokines in irritable bowel syndrome (IBS). Gastroenterology 138 (5, Suppl 1):S628

    Google Scholar 

  29. Swidsinski A, Ladhoff A, Pernthaler A, Swidsinski S, Loening-Baucke V, Ortner M, Weber J, Hoffmann U, Schreiber S, Dietel M, Lochs H (2002) Mucosal flora in inflammatory bowel disease. Gastroenterology 122(1):44–54

    Article  PubMed  Google Scholar 

  30. Swidsinski A, Weber J, Loening-Baucke V, Hale LP, Lochs H (2005) Spatial organization and composition of the mucosal flora in patients with inflammatory bowel disease. J Clin Microbiol 43(7):3380–3389

    Article  PubMed Central  PubMed  Google Scholar 

  31. Piche T, Barbara G, Aubert P, Bruley des Varannes S, Dainese R, Nano JL, Cremon C, Stanghellini V, De Giorgio R, Galmiche JP, Neunlist M (2009) Impaired intestinal barrier integrity in the colon of patients with irritable bowel syndrome: involvement of soluble mediators. Gut 58(2):196–201

    Article  CAS  PubMed  Google Scholar 

  32. Barbara G, Stanghellini V, De Giorgio R, Cremon C, Cottrell GS, Santini D, Pasquinelli G, Morselli-Labate AM, Grady EF, Bunnett NW, Collins SM, Corinaldesi R (2004) Activated mast cells in proximity to colonic nerves correlate with abdominal pain in irritable bowel syndrome. Gastroenterology 126(3):693–702

    Article  PubMed  Google Scholar 

  33. Barbara G, Wang B, Stanghellini V, de Giorgio R, Cremon C, Di Nardo G, Trevisani M, Campi B, Geppetti P, Tonini M, Bunnett NW, Grundy D, Corinaldesi R (2007) Mast cell-dependent excitation of visceral-nociceptive sensory neurons in irritable bowel syndrome. Gastroenterology 132(1):26–37

    Article  CAS  PubMed  Google Scholar 

  34. Cenac N, Andrews CN, Holzhausen M, Chapman K, Cottrell G, Andrade-Gordon P, Steinhoff M, Barbara G, Beck P, Bunnett NW, Sharkey KA, Ferraz JG, Shaffer E, Vergnolle N (2007) Role for protease activity in visceral pain in irritable bowel syndrome. J Clin Invest 117(3):636–647

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  35. Vernier G, Sendid B, Poulain D, Colombel JF (2004) Relevance of serologic studies in inflammatory bowel disease. Curr Gastroenterol Rep 6(6):482–487

    Article  PubMed  Google Scholar 

  36. Gewirtz AT (2006) Flag in the crossroads: flagellin modulates innate and adaptive immunity. Curr Opin Gastroenterol 22(1):8–12

    Article  CAS  PubMed  Google Scholar 

  37. Elson C, Cong Y, McCracken VJ, Dimmitt RA, Lorenz RG, Weaver CT (2005) Experimental models of inflammatory bowel disease reveal innate, adaptive, and regulatory mechanisms of host dialogue with the microbiota. Immunol Rev 206:260–276

    Article  PubMed  Google Scholar 

  38. Barnich N, Carvalho FA, Glasser AL et al (2007) CEACAM6 acts as a receptor for adherent-invasive E. coli, supporting ileal mucosa colonization in Crohn disease. J Clin Invest 117:1566–1574

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  39. Frank DN, St Amand AL, Feldman RA, Boedeker EC, Harpaz N, Pace NR (2007) Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases. Proc Natl Acad Sci USA 104:13780–13785

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  40. Turner JR (2006) Molecular basis of epithelial barrier regulation: from basic mechanisms to clinical application. Am J Pathol 169:1901–1909

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  41. Lee J, Mo JH, Katakura K et al (2006) Maintenance of colonic homeostasis by distinctive apical TLR9 signalling in intestinal epithelial cells. Nat Cell Biol 8:1327–1336

    Article  CAS  PubMed  Google Scholar 

  42. Barrett JC, Hansoul S, Nicolae DL et al (2008) Genome-wide association defines more than 30 distinct susceptibility loci for Crohn’s disease. Nat Genet 40:955–962

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  43. Lesage S, Zouali H, Cézard JP et al (2002) CARD15/NOD2 mutational analysis and genotype–phenotype correlation in 612 patients with inflammatory bowel disease. Am J Hum Genet 70:845–857

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  44. Economou M, Trikalinos TA, Loizou KT, Tsianos EV, Ioannidis JP (2004) Differential effects of NOD2 variants on Crohn’s disease risk and phenotype in diverse populations: a metaanalysis. Am J Gastroenterol 99:2393–2404

    Article  CAS  PubMed  Google Scholar 

  45. Smythies LE, Sellers M, Clements RH et al (2005) Human intestinal macrophages display profound inflammatory anergy despite avid phagocytic and bacteriocidal activity. J Clin Invest 115:66–75

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  46. Kamada N, Hisamatsu T, Okamoto S et al (2008) Unique CD14 intestinal macrophages contribute to the pathogenesis of Crohn disease via IL-23/IFN-gamma axis. J Clin Invest 118:2269–2280

    CAS  PubMed Central  PubMed  Google Scholar 

  47. Hedl M, Li J, Cho JH, Abraham C (2007) Chronic stimulation of Nod2 mediates tolerance to bacterial products. Proc Natl Acad Sci USA 104:19440–19445

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  48. Burkitt DP (1971) Epidemiology of cancer of the colon and the rectum. Cancer 28:3220

    Google Scholar 

  49. Gibson GR, Cummings JH, Macfarlane GT et al (1990) Alternative pathways for hydrogen disposal during fermentation in the human colon. Gut 31:679–683

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  50. Roedinger WEW, Moore J, Babidge W (1997) Colonic sulfide in pathogenesis and treatment of ulcerative colitis. Dig Dis Sci 42:1571–1579

    Article  Google Scholar 

  51. Reddy BS, Weinsenburger JH, Wynder EL (1975) Effect of high-risk and low-risk diets for colon carcinogenesis of fecal microflora and steroids in man. J Nutr 105:878–884

    CAS  PubMed  Google Scholar 

  52. De Giorgio R, Blandizzi C (2010) Targeting enteric neuroplasticity: diet and bugs as new key factors. Gasroenterology 138:1663–1666

    Article  Google Scholar 

  53. Barbara G, Stanghellini V, Cremon C, De Giorgio R, Fronzoni L, Serra M, Corinaldesi R (2009) Aminosalicylates and other anti-inflammatory compounds for irritable bowel syndrome. Dig Dis 27(Suppl 1):115–121

    Article  PubMed  Google Scholar 

Download references

Conflict of interest

None.

Author information

Authors and Affiliations

  1. Department of Clinical Medicine, St. Orsola-Malpighi Hospital, University of Bologna, Building No. 5, Via Massarenti, 9, 40138, Bologna, Italy

    Vincenzo Stanghellini, Giovanni Barbara, Cesare Cremon, Rosanna Cogliandro, Alexandra Antonucci, Veronica Gabusi, Chiara Frisoni, Roberto De Giorgio, Valentina Grasso, Mauro Serra & Roberto Corinaldesi

Authors
  1. Vincenzo Stanghellini
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Giovanni Barbara
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Cesare Cremon
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Rosanna Cogliandro
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Alexandra Antonucci
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Veronica Gabusi
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Chiara Frisoni
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Roberto De Giorgio
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Valentina Grasso
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Mauro Serra
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Roberto Corinaldesi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Vincenzo Stanghellini.

Additional information

The article has been retracted upon request of the authors as it contains similarities with paragraphs of previously published articles: Abraham C, Cho H.J. N Engl J Med 2009; 361:2066-2078, SE McGarr, JM Ridlon, PB Hylemon (2005) J Clin Gastroenterol 39(2):98-109, Barbara G (2006) Mucosal Barrier Defects in Irritable Bowel Syndrome. Who Left the Door Open? Am J Gastroenterol 101.1295-1298, Barbara G, Stanghellini V, Cremon C (2008) Probiotics and irritable bowel syndrome: rationale and clinical evidence for their use. J Clin Gastroenterol 42(suppl)S214-S217 without any proper reference to the above-mentioned articles.Authors acknowledge full responsibility for this unfortunate situation which they attribute to an honest mistake due to erroneous submission of a preliminary version of the manuscript and not to an intentional plagiarism. They apologize with Editor in Chief and readers as well as with authors of the original articles and agreed to the retraction.

An erratum to this article can be found at http://dx.doi.org/10.1007/s11739-014-1164-6.

About this article

Cite this article

Stanghellini, V., Barbara, G., Cremon, C. et al. RETRACTED ARTICLE: Gut microbiota and related diseases: clinical features. Intern Emerg Med 5 (Suppl 1), 57–63 (2010). https://doi.org/10.1007/s11739-010-0451-0

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11739-010-0451-0

Keywords

Search

Navigation